title: Delaying Renal Transplant after Radical Prostatectomy for Low-Risk Prostate Cancer.
abstract: To minimize the recurrence of a previously treated neoplasm in organ recipients, a period of 2 to 5 years without recurrence is advocated for most malignancies. However, prostate cancer is different because of its biological properties, diagnosis, and treatment. Most prostate cancers are detected at a low stage and demonstrate slow growth after detection. Definitive treatment with radical prostatectomy affords excellent results. Renal transplant candidates with early-stage prostate cancer have a higher risk of dying on dialysis than dying from prostate cancer; therefore, renal transplant candidates with organ-confined prostate cancer should be immediately considered for transplant.
authors.affiliation: From the Department of General Surgery, Baskent University School of Medicine, Istanbul, Turkey.
authors.forename: Ümit
authors.initials: Ü
authors.lastname: Özçelik
authors.forename: Hüseyin Yüce
authors.initials: HY
authors.lastname: Bircan
authors.forename: Feza
authors.initials: F
authors.lastname: Karakayalı
authors.forename: Gökhan
authors.initials: G
authors.lastname: Moray
authors.forename: Alp
authors.initials: A
authors.lastname: Demirağ
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology / Q000601:surgery*; D001706:Biopsy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007610:Kallikreins / Q000097:blood; D007676:Kidney Failure, Chronic / Q000150:complications / Q000175:diagnosis / Q000601:surgery*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D018579:Patient Selection; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000150:complications / Q000473:pathology / Q000601:surgery*; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D061665:Time-to-Treatment; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen